Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Editors In Chief

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany

Stefan Zeuzem, MD, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, Intercept, Janssen, and fees for non-CME/CE services from AbbVie, Gilead Sciences, Janssen, and Merck/MSD. Dr. Zeuzem has disclosed in previous editions that he had served as a consultant or on advisory boards for Abbott, AbbVie, Achillion, Anadys, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, iTherX, Janssen, Merck, Novartis, Pfizer, Pharmasset, Presidio, Roche, Santaris, Tibotec/Janssen, and Vertex and had served on speaker bureaus for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and Roche.

Author

Francesco Negro, MD

Professor
Divisions of Gastroenterology and Hepatology and of Clinical Pathology
University Hospitals
Geneva, Switzerland

Francesco Negro, MD, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, and Merck and funds for research support from Gilead Sciences. Dr. Negro has disclosed in previous editions that he had received consulting fees from Bristol-Myers Squibb, Janssen, MSD, and Novartis and funds for research support from MSD and Roche.

Staff

Jennifer M. Blanchette, PhD

Managing Editor

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

Taryn O'Loughlin Gross, PhD

Editorial Manager

Taryn O’Loughlin Gross, PhD, has disclosed that she has received fees for non-CME services from Salix Pharmaceuticals, Saluda Medical, and Shionogi.

Tiffany Hensley-McBain, PhD

Clinical Editor

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.

Additional Disclosure Information

The following faculty and staff have previously contributed to the content of this module and disclosed the following potential conflicts of interest:

Nezam H. Afdhal, MD, FRCPI, disclosed that he had served as a consultant or on advisory boards for AbbVie, Achillion, Boehringer Ingelheim, Biogen, Biolex, Echosens, FibroGen, Gilead Sciences, GlaxoSmithKline, Idera, Janssen, Kadmon, Ligand, Medgenics, Merck, Novartis, Spring Bank, and Vertex; had received funds for research support from Abbott, AbbVie, Bristol-Myers Squibb, Echosens, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, Quest, and Vertex; and had held stock options for Medgenics and Spring Bank at the time he contributed to this module.

Norah Terrault, MD, MPH, disclosed that she had served as a consultant for Biotest, Bristol-Myers Squibb, Gilead Sciences, Merck, Roche/Genentech, and Siemens and had received funds for research support from Eisai, Gilead Sciences, Novartis, Roche/Genentech, and Vertex at the time she contributed to this module.

Megan Cartwright, PhD; Jenny Schulz, PhD; Sheralee Connors, MA; Hashem El-Serag, MD, MPH; Krista Marcello; Kiran Mir-Hudgeons, PhD; Kimberly Y. Smith, MD, MPH; Taryn O’Loughlin Gross, PhD; Kerry Garza, PhD; Lisa Gargano, PhD, MPH; and Heather Stieglitz, PhD, had no real or apparent conflicts of interest to report at the time they contributed to this module.

Disclaimer

The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Contact Information

If you have technical queries about using this site, please contact: techhelp@clinicaloptions.com.

If you have credit related queries or a complaint, please contact: skelley@clinicaloptions.com.

inPractice Hepatology current certification period
Release Date: March 2, 2020
Expiration Date: March 1, 2021

Target Audience

This program is intended for physicians and other healthcare professionals involved in the medical management of patients with or at risk of viral hepatitis.

Goal:

The goal of this activity is to improve learners’ knowledge and competence regarding the clinical management of patients with viral hepatitis.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

Commercial Support

This program is supported by educational grants from AbbVie.


inPractice HIV current certification period
Release Date: November 16, 2020
Expiration Date: November 15, 2021

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the management of patients with HIV.

Goal:

The goal of this activity is to provide a comprehensive clinical reference resource on the prevention, diagnosis, and treatment of HIV disease.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

Commercial Support:

This program is supported by educational grants from Gilead Sciences, Inc., Merck Sharp & Dohme Corp. and ViiV Healthcare.


For inPractice Hepatology and HIV

Physician Continuing Medical Education (for Point of Care CME activities)
CCO

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


CCO designates this internet point-of-care activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Credit (Point of Care CME)

inPractice offers physicians AMA PRA Category 1 CreditTM for participation in this individual Internet point-of-care activity. Physicians may claim 0.5 credits per search. To claim point-of-care (PoC) CME credit through inPractice, eligible physicians must complete the following steps:

  1. Register online at http://www.inpractice.com
  2. Execute a search or submit a clinical question
  3. Review the applicable clinical sources
  4. Click the "Claim CME Credit" button at the top right corner of the content you have viewed
  5. Complete the simple evaluation questions addressing clinical application of learnings from the sources you have consulted

After submitting the evaluation, you will be presented with your online CME certificate as a pdf file. Records of all CME activities completed can be found on the "My CME" page.